STIMULATE-ICP

United Kingdom of Great Britain and Northern Ireland
|
2022
  • Adults (18-64 years)
  • General population
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Colchicine
  • Antihistamines
  • Rivaroxaban